Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8Colorectal Neoplasms 5Carcinoma, Renal Cell 5Rectal Neoplasms 4Prostatic Neoplasms 4Melanoma 4Colonic Neoplasms 4Pancreatic Neoplasms 3Kidney Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Carcinoma In Situ 2Wilms Tumor 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Salivary Gland Neoplasms 1

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Ferrosoferric Oxide 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Intraductal Neoplasms × Immunohistochemistry × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡